TRIB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TR

Mkt Cap

$6.3M

Volume

27.84K

Loading chart

TR

TRIBTrinity Biotech plc

TRIB

Pay with—

Available Balance0.00

TR

Mkt Cap

$6.4M

Volume

27.84K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate UpdateTrinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.GlobeNewswire Inc. · Aug 28, 2026

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held SharesTrinity Biotech plc received a non-compliance notice from Nasdaq on February 19, 2026, for failing to maintain the minimum market value of publicly held shares (MVPHS) of $15,000,000 required under Nasdaq Listing Rule 5450(b). The company has 180 calendar days until August 18, 2026, to regain compliance or face potential delisting. The ADSs will continue trading on Nasdaq Global Select Market under the symbol 'TRIB' during this period.GlobeNewswire Inc. · Feb 20, 2026

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price RequirementTrinity Biotech plc received a non-compliance notice from Nasdaq on February 11, 2026, for failing to maintain the minimum bid price of $1.00 per share. The company has 180 calendar days until August 10, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. Management is evaluating options to cure the deficiency while the ADSs continue trading on the Nasdaq Global Select Market.GlobeNewswire Inc. · Feb 13, 2026

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer TestTrinity Biotech collaborates with a bioinformatics company to enhance its EpiCapture prostate cancer test, which uses DNA methylation patterns to monitor disease progression non-invasively.GlobeNewswire Inc. · Nov 14, 2025

Biosensors Market Size Expected to Reach USD 68.72 Billion by 2034The global biosensors market is expected to grow from USD 30.04 billion in 2024 to USD 68.72 billion by 2034, with a CAGR of 8.64%. North America dominates the market, while Asia-Pacific shows the fastest growth potential, driven by chronic disease management and technological advancements.GlobeNewswire Inc. · Aug 22, 2025

Trinity Biotech Appoints Paul Tivnan as Non-Executive DirectorTrinity Biotech has appointed Paul Tivnan, a finance and energy sector executive with over 25 years of leadership experience, to its Board of Directors as a Non-Executive Director.GlobeNewswire Inc. · Aug 21, 2025

Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing ServiceTrinity Biotech received NYSDOH approval for its PreClara™ Ratio biomarker test to assess preeclampsia risk in pregnant women, with planned rollout in Q3 2025. The test aims to provide clinicians with time-sensitive insights for managing hypertensive pregnancy disorders.GlobeNewswire Inc. · Aug 14, 2025

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing ServiceTrinity Biotech launched a new FDA-cleared sFlt-1/PlGF biomarker test for managing hypertensive disorders of pregnancy, offering clinicians a tool to assess preeclampsia risk with potential significant cost savings and improved patient outcomes.GlobeNewswire Inc. · Aug 7, 2025

Hemoglobin A1c (HbA1c) Testing Market Projected to Reach $1.83 Billion by 2024, Growth Fueled by Rising Prevalence of Diabetes - Global Long-term Forecasts to 2028 and 2033The global hemoglobin A1c (HbA1c) testing market is expected to grow from $1.66 billion in 2023 to $1.83 billion by 2024, driven by the increasing prevalence of diabetes and advancements in diagnostic technology. The Asia-Pacific region is anticipated to experience the fastest growth, while North America remains the largest market.GlobeNewswire Inc. · Jan 3, 2025

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation PlanTrinity Biotech has entered into amended agreements with its primary lender, Perceptive Advisors, to provide additional liquidity and support its Comprehensive Transformation Plan, which includes the development of its continuous glucose monitoring (CGM) technology.GlobeNewswire Inc. · Dec 24, 2024

to start trading

TR

TRIBTrinity Biotech plc

TRIB

Pay with—

Available Balance0.00

Your PositionYou don't own any TRIB yet.

Related Tickers

Earnings